GGGrigory V. Garushyan

Grigory V. Garushyan

*This is an algorithmically generated author record based on publicly available information.

Grigory V. Garushyan has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Maria D. Ardatskaya

    Central State Medical Academy

    1 shared publication
  • Ардатская Мария Дмитриевна

    ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской Федерации

    1 shared publication
  • Гарушьян Григорий Валерьевич

    ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий» ФМБА России

    1 shared publication

Latest Publications

  • Open Access

    Restoration of microbiota balance using spore-forming probiotic microorganisms: a review

    by Maria D. Ardatskaya, Grigory V. Garushyan, Ардатская Мария Дмитриевна, Гарушьян Григорий Валерьевич

    Intestinal dysbiosis is a common condition associated with a wide range of diseases. Choosing the optimal probiotic therapy remains challenging due to the variety of available strains. Spore-forming probiotics, particularly Bacillus clausii, exhibit high resistance to aggressive gastrointestinal factors and can rapidly restore the gut microbiota. Aim – to summarize current data on the mechanisms of action and clinical efficacy of B. clausii in correcting dysbiotic disorders. A review of recent literature was performed, including systematic reviews, randomized controlled trials, real-world studies (PEGASO), and preclinical studies focusing on B. clausii. B. clausii exerts antagonistic, immunomodulatory, and metabolic effects, and restores intestinal barrier function. According to a systematic review (C. Acosta-Rodríguez-Bueno et al., 2022), a 7-day course of B. clausii significantly reduces the duration of acute diarrhea by 1–2 days and decreases the risk of antibiotic-associated diarrhea by 47–60%. In a prospective study (H. Dang et al., 2024) in children with persistent diarrhea, symptom resolution was achieved in 87.5% of patients by day 7, along with a decrease in fecal calprotectin and an increase in secretory IgA levels. In real-world practice (PEGASO study, С. Giua et al., 2024), 89% of patients rated the efficacy as “good” or “excellent,” adherence to the 7-day course was 94%, and the incidence of adverse events was 2.1%. An experimental study (M. Salem et al., 2025) revealed suppression of the TXNIP/NLRP3 inflammasome cascade and restoration of the gut microbiota following B. clausii treatment in a colitis model. B. clausii is a universal means of primary correction of dysbiosis, capable of restoring the gut microbiota and resolving diarrhea within 7 days. Owing to its transient persistence, after the course the residual disturbances can be objectively assessed, allowing for personalized therapy with other probiotics (lactobacilli, bifidobacteria, Saccharomyces boulardii, etc.) depending on the remaining alterations of the gut microbiota.